BioCentury
ARTICLE | Clinical News

Debiopharm antibiotic passes Phase II ABSSSI test

January 10, 2017 11:59 PM UTC

Debiopharm Group (Lausanne, Switzerland) said antibiotic candidate Debio 1450 met the primary endpoint of non-inferiority to vancomycin plus linezolid across all tested Staphylococcus species in a Phase II trial to treat acute bacterial skin and skin structure infections. The trial evaluated IV and oral formulations of Debio 1450 at two dose levels with ABSSSI due to staphylococci, including methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA).

In the trial’s microbiological intent-to-treat (mITT) population of 284 patients, low-dose Debio 1450 led to an early clinical response rate at 48-72 hours of 94.6% vs. 91.1% for vancomycin plus linezolid, while high-dose Debio 1450 led to a 90.1% early clinical response rate. Debio 1450 is a small molecule prodrug inhibitor of the bacterial fabl enoyl-(acyl carrier protein) reductase...

BCIQ Company Profiles

Debiopharm Group